Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma"
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma | Zhou et al. Journal of Experimental Clinical Cancer Research 2011 30 2 http www.jeccr.eom content 30 1 2 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Expression and prognostic significance of cancer-testis antigens CTA in intrahepatic cholagiocarcinoma Jin-xue Zhou1t Yin l_i2 Sun-xiao Chen 3 An-mei Deng3 Abstract Background Cancer-testis antigens CTAs are suitable targets for cancer-specific immunotherapy. The aim of the study is to investigate the expression of CTAs in intrahepatic cholagiocarcinoma IHCC and evaluate their potential therapeutic values. Methods Eighty-nine IHCC patients were retrospectively assessed for their expression of CTAs and H_A Class I by immunohistochemistry using the following antibodies MA454 recognizing MAGE-A1 57B recognizing multiple MAGE-A MAGE-A3 A4 E978 recognizing NY-ESO-1 and EMR8-5 recognizing H_A class I. The clinicopathological and prognostic significance of individual CTA markers and their combination were further evaluated. Results The expression rates of MAGE-A1 MAGE-A3 4 and NY-ESO-1 were 29.2 27.0 and 22.5 respectively. The concomitant expression of CTAs and H_A class I antigen was observed in 33.7 of the IHCC tumors. We found that positive MAGE-3 4 expression correlated with larger tumor size 5 cm tumor recurrence and poor prognosis. Moreover we identified 52 cases 58.4 of IHCC patients with at least one CTA marker expression and this subgroup displayed a higher frequency of larger tumor size and a shorter survival than the other cases. Furthermore expression of at least one CTA marker was also an independent prognostic factor in patients with IHCC. Conclusion Our data suggest that specific immunotherapy targeted CTAs might be a novel treatment option for IHCC patients. Introduction Intrahepatic cholagiocarcinoma IHCC is a relatively uncommon malignancy comprising approximately 5 -10 of the liver cancers and both its incidence and mortality have increased in recent years in China and other .